Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis
Open Access
- 10 December 2020
- journal article
- research article
- Published by Hindawi Limited in Disease Markers
- Vol. 2020, 1-10
Abstract
Background. Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional tumor markers is essential for LC diagnosis. Patients and Methods. Blood samples were collected from 132 LC cases and 118 benign lung disease (BLD) controls. The expression levels of ten serum tumor markers (CYFR21, CEA, NSE, SCC, CA15-3, CA 19-9, CA 125, CA50, CA242, and CA724) were assayed, and that the expression in the levels of tumor markers were evaluated, isolated, and combined in different patients. The performance of the biomarkers was analyzed by receiver operating characteristic (ROC) analyses, and the difference between combinations of biomarkers was compared by Chi-square () tests. Results. As single markers, CYFR21 and CEA showed good diagnostic efficacy for nonsmall cell lung cancer (NSCLC) patients, while NSE and CEA were the most sensitive in the diagnosis of small cell lung cancer (SCLC). The area under the curve (AUC) value was 0.854 for the panel of four biomarkers (CYFR21, CEA, NSE, and SCC), 0.875 for the panel of six biomarkers (CYFR21, CEA, NSE, SCC, CA125, and CA15-3), and 0.884 for the panel of ten markers (CYFR21, CEA, NSE, SCC, CA125, CA15-3, CA19-9, CA50, CA242, and CA724). With a higher sensitivity and negative predictive value (NPV), the diagnostic accuracy of the three panels was better than that of any single biomarker, but there were no statistically significant differences among them (all values > 0.05). However, the panel of six carbohydrate antigen (CA) biomarkers (CA125, CA15-3, CA19-9, CA50, CA242, and CA724) showed a lower diagnostic value (AUC: 0.776, sensitivity: 59.8%, specificity: 73.0%, and NPV: 60.4%) than the three panels ( value < 0.05). The performance was similar even when analyzed individually by LC subtypes. Conclusion. The biomarkers isolated are elevated for different types of lung cancer, and the panel of CYFR21, CEA, NSE, and SCC seems to be a promising serum biomarker for the diagnosis of lung cancer, while the combination with carbohydrate antigen markers does not improve the diagnostic efficacy.Keywords
Funding Information
- ‘139’ Incubation Program for high-level medical talents in Guangxi (2018BJ10509, AB16380152)
This publication has 29 references indexed in Scilit:
- CA-125 in Disease Progression and Treatment of LymphangioleiomyomatosisChest, 2018
- Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot studyWorld Journal of Surgical Oncology, 2017
- The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung CancerBioMed Research International, 2017
- Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung CancerJournal of Cancer Prevention, 2016
- Lung Cancer Statistics2015
- The 2015 World Health Organization Classification of Lung TumorsJournal of Thoracic Oncology, 2015
- International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in womenLung Cancer, 2014
- Recurrence Patterns in Patients With Early Stage Non-Small Cell Lung Cancers Undergoing Positive Pleural Lavage CytologyThe Annals of Thoracic Surgery, 2007
- Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.1998
- Study of a New Tumor Marker, CYFRA21-1, in Malignant and Nonmalignant DiseasesTumor Biology, 1994